Mitsubishi UFJ Trust & Banking Corp Trims Holdings in Illumina, Inc. (NASDAQ:ILMN)

Mitsubishi UFJ Trust & Banking Corp lessened its stake in Illumina, Inc. (NASDAQ:ILMN) by 12.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 72,884 shares of the life sciences company’s stock after selling 10,367 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Illumina were worth $9,739,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. WCM Investment Management LLC grew its position in shares of Illumina by 26.6% in the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock worth $551,625,000 after acquiring an additional 867,673 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Illumina by 0.8% during the fourth quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company’s stock worth $454,617,000 after purchasing an additional 27,618 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Illumina by 1.8% in the third quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock worth $354,933,000 after purchasing an additional 48,018 shares during the period. Janus Henderson Group PLC increased its stake in Illumina by 40.5% during the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after purchasing an additional 625,245 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Illumina by 4.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company’s stock worth $164,334,000 after purchasing an additional 54,319 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ILMN has been the subject of several research reports. Barclays reaffirmed an “underweight” rating on shares of Illumina in a report on Tuesday, March 11th. Citigroup lowered their target price on Illumina from $130.00 to $90.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Piper Sandler boosted their price objective on Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Hsbc Global Res downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. Finally, Morgan Stanley cut their target price on Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $140.90.

Illumina Price Performance

NASDAQ:ILMN opened at $80.00 on Friday. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The business’s 50-day moving average price is $102.80 and its 200 day moving average price is $126.81. Illumina, Inc. has a 52-week low of $79.30 and a 52-week high of $156.66. The firm has a market cap of $12.67 billion, a P/E ratio of -10.42, a PEG ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, sell-side analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.